AOAna Cecilia Amado Xavier de Oliveira

Ana Cecilia Amado Xavier de Oliveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Cecilia Amado Xavier de Oliveira has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In vitro inhibition of mouse liver microsomal cytochrome P450 (CYP) subfamilies by the diterpenes synagrantol A and G isolated from the latex of Euphorbia umbellata

    by Thaís de Sousa Rolim, João Batista de Freitas Tostes, Carlos Henrique Ramos, Ana Cecilia Amado Xavier de Oliveira, Francisco José Roma Paumgartten, Davyson Moreira Lima, Antonio Carlos Siani

    Phorbol esters are diterpenoids found in the genus Euphorbia (Euphorbiaceae). Synagrantol A (Phorbol-3,4,12,13-tetraacetate-20-phenylacetate) and G (20-deoxyphorbol-3,4,12-triacetate-13-phenylacetate) are phorbol esters from Euphorbia umbellata latex that are under investigation for their anti-HIV properties. This study describes their isolation using chromatographic techniques and their inhibitory effects on four cytochrome P450 (CYP) enzyme subfamilies extracted from mouse liver microsomes after induction by β-naphthoflavone (CYP1A, CYP2A), phenobarbital (CYP2B), or dexamethasone (CYP3A). After euthanasia and liver extraction, enzyme activity was assessed in treated and untreated animal’s samples via the dealkylation of ethoxyresorufin (CYP1A1), methoxyresorufin (CYP1A2), pentoxyresorufin (CYP2B), and N-methyl-erythromycin (CYP3A). Synagrantol A or G (100 µM) and α-naphthoflavone (CYP1A1/2 positive control) were added to microsomal suspensions, followed by substrate addition. Inhibition was measured by the production of resorufin in a spectrofluorometer or formaldehyde in a spectrophotometer (specific for CYP3A). The induction factor (IF) was 2.9 (CYP1A1), 2.43 (CYP1A2), 2.4 (CYP2B), and 1.2 (CYP3A). Synagrantol A and G significantly inhibited CYP1A1 (>90%), followed by CYP1A2 (84% and 64%, respectively). CYP2B inhibition was lower (34% and 49%), and CYP3A inhibition was the least significant (18% and 32%). Since these CYPs metabolize up to 60% of marketed drugs, further research on their metabolic interactions with phorbol esters is essential to ensure the safety of products containing these compounds.


  • Open Access

    Ethical considerations on placebo-controlled vaccine trials in pregnant women

    by Ana Cecilia Amado Xavier de Oliveira, Francisco José Roma Paumgartten

    Placebo use in clinical trials, whenever a proven effective treatment exists, is one of the most debated topics in contemporary research ethics. This article addresses the ethical framework for placebo use in clinical trials assessing vaccine efficacy in pregnant women. Vaccine trial participants are healthy at the outset and some must be infected during the study to demonstrate the product’s efficacy, meaning that placebo-treated participants are under risk of serious and irreversible harm. If effective vaccines exist, such risk precludes placebo use. This interdiction should be extended to any clinical trial of vaccine efficacy in pregnant women, because a demonstration of clinical efficacy in nonpregnant individuals and comparable immunogenic responses in pregnant women are predictors of efficacy in pregnancy as well. Moreover, product effectiveness in real-world use scenarios can be ascertained by observational studies conducted after its inclusion in vaccination campaigns.

  • Open Access

    Consideraciones éticas sobre los ensayos de vacunas controlados con placebo en mujeres embarazadas

    by Ana Cecilia Amado Xavier de Oliveira, Francisco José Roma Paumgartten

    Resumen El uso de placebo en ensayos clínicos es uno de los principales temas debatidos sobre la ética en investigación contemporánea cuando existe un tratamiento eficaz probado. Este artículo aborda la ética en el uso de placebo en ensayos clínicos sobre la eficacia de vacuna en mujeres embarazadas. Las participantes en los ensayos de vacunas estaban sanas al inicio del estudio, y algunas fueron vacunadas durante el estudio para demostrar la eficacia del producto. Las participantes tratadas con placebo corren el riesgo de sufrir daños graves e irreversibles. Si existen vacunas efectivas, este riesgo impide el uso de placebo. Este impedimento debe extenderse a cualquier ensayo clínico de eficacia de vacuna en embarazadas, pues la eficacia clínica demostrada en mujeres no embarazadas y las respuestas inmunogénicas comparables con las embarazadas son predictores de eficacia en el embarazo. Además, la efectividad del producto se constata en estudios observacionales realizados tras las campañas de vacunación.

  • Open Access

    Considerações éticas sobre estudos de vacina controlada com placebo em gestantes

    by Ana Cecilia Amado Xavier de Oliveira, Francisco José Roma Paumgartten

    Resumo O uso de placebo em ensaios clínicos, quando um tratamento comprovadamente eficaz existe, é um dos principais tópicos debatidos na ética em pesquisa contemporânea. Este artigo aborda o quadro ético para o uso de placebo em ensaios clínicos que avaliam a eficácia de vacina em gestantes. Participantes em ensaios de vacina são saudáveis no início e alguns devem ser inoculados durante o estudo para demonstrar a eficácia do produto. Ou seja, participantes tratados com placebo estão sob risco de danos graves e irreversíveis. Se existirem vacinas eficazes, esse risco impede o uso de placebo. Essa interdição deve ser estendida a qualquer ensaio clínico de eficácia de vacina em gestantes, pois a demonstração de eficácia clínica em não gestantes e as respostas imunogênicas comparáveis em gestantes também são preditoras de eficácia na gravidez. Ademais, a eficácia do produto em cenários reais de uso pode ser verificada por estudos observacionais realizados após sua inclusão em campanhas de vacinação.


  • Protective effects of a chemically characterized extract fromsolanum torvumleaves on acetaminophen-induced liver injury

    by Gabriela R. de Souza, Ana Cecilia A. X. De-Oliveira, Vitor Soares, Thamyris Perez De-Souza, Nancy S. Barbi, Francisco J. R. Paumgartten, Antonio J. R. da Silva

    Distinct parts of Solanum torvum Swartz. (Solanaceae) are popularly used for a variety of therapeutic purposes. This study determined the phytochemical composition of a phenolic fraction of S. torvum leaf aqueous extract and investigated its antioxidant and liver-protective properties. A phenolic compound-enriched fraction, or phenolic fraction (STLAE-PF) of an infusion (STLAE) of S. torvum leaves, was tested in vitro (antagonism of H2O2 in cytotoxicity and DCF assays with HepG2/C3A cells), and in vivo for antioxidant activity and protective effects against acetaminophen (APAP)-induced liver injury in mice. Thirty-eight compounds (flavonoids, esters of hydroxycinnamic acid, and chlorogenic acid isomers) were tentatively identified (high-performance liquid chromatography coupled to high-resolution electrospray mass spectrometry) in the STLAE-PF fraction. In vitro assays in HepG2/C3A cells showed that STLAE-PF and some flavonoids contained in this phenolic fraction, at noncytotoxic levels, antagonized in a concentration-dependent manner the effects of a powerful oxidant agent (H2O2). In C57BL/6 mice, oral administration of STLAE (600 and 1,200 mg/kg bw) or STLAE-PF (300 mg/kg bw) prevented the rise in serum transaminases (ALT and AST), depletion of reduced glutathione (GSH) and elevation of thiobarbituric acid reactive species (TBARs) levels in the liver caused by APAP (600 mg/kg bw, i.p.). The hepatoprotective effects of STLAE-PF (300 mg/kg bw) against APAP-caused liver injury were comparable to those of N-acetyl-cysteine (NAC 300 or 600 mg/kg bw i.p.). These findings indicate that a phenolic fraction of S. torvum leaf extract (STLAE-PF) is a new phytotherapeutic agent potentially useful for preventing/treating liver injury caused by APAP overdosing.


  • On the safety and effectiveness of COVID-19 vaccines, certainties and uncertainties

    by Fundação Oswaldo Cruz (Ensp/Fiocruz) Escola Nacional de Saúde Pública Sérgio Arouca, Ana Cecilia Amado Xavier de Oliveira, Isabella Fernandes Delgado, Fundação Oswaldo Cruz (Incqs/Fiocruz) Instituto Nacional de Controle de Qualidade Em Saúde, Francisco José Roma Paumgartten

    Introduction: The COVID-19 vaccines in use (inactivaded virus, encapsulated m-RNA, non-replicating adenovirus-vectored DNA) were clinically tested in randomized placebocontrolled phase-3 studies. Objective: To address certainties and uncertainties about safety and effectiveness of COVID-19 vaccines that were approved for use in various countries. Method: The evidence provided by clinical studies on the efficacy and safety of COVID-19 vaccines was critically appraised. Results: COVID-19 vaccines proved to be efficacious and safe in clinical trials. Adverse events were mostly those of minor severity commonly noted with other vaccines such as injection site pain, mild flu-like symptoms, headache and asthenia. Although being very rare, anaphylaxis-like reactions were noted with mRNA vaccines. Uncertainties regarding vaccine effectiveness refer mainly to the (long-term) duration of immunity provided by vaccination, the degree of protection conferred to elderly people, and how effective vaccines are against emerging SARS-CoV-2 variants. There are few uncertainties about vaccine safety including the absence of clinical trial data in pregnant women (and the impact on the unborn child), children and adolescents. Conclusions: Notwithstanding the knowledge gaps about effectiveness and safety of COVID-19 vaccines (to be further addressed by observational studies), there is overwhelming evidence that public health benefits of vaccination by far outweigh any foreseeable risk.


  • Open Access

    Transplacental Transfer of Primaquine and Neurobehavioral Development of Prenatally Exposed Rats

    by Klaus M. Becker, Lorenna Rosa, Manoella S. B. Fernandes, Rosangela R. de Carvalho, Ana Cecilia X. De-Oliveira, Davyson L. Moreira, Francisco J. R. Paumgartten

    Primaquine (PQ) not only eliminates P. falciparum gametocytes but also kills liver dormant forms of P. vivax and P. ovale. Owing to these unique therapeutic properties, it is an essential drug. Although PQ has been used for over 70 years, its toxicological database has gaps such as the absence of studies on its reproductive and developmental toxicity and kinetics in pregnancy. This study investigated the transplacental transfer of PQ and the effects of intrauterine exposure on the postnatal growth, survival, and neurobehavioral development of the offspring. PQ kinetics and transplacental transfer were investigated in rats treated orally (40mg.kg·bw−1) on gestation day (GD) 21. PQ was analyzed by high-performance liquid chromatography with diode array ultraviolet detection. To evaluate effects of intrauterine exposure on postnatal development, dams were treated orally with PQ (20mg.kg·bw−1·d−1) or water (controls) on GD 021. Postnatal survival, body weight gain, somatic maturation, and reflex acquisition were evaluated. The open field test (OF) was conducted on PND 25. PQ concentration in the fetal plasma was nearly half that in maternal plasma. Except for increase in pregnancy loss, no effects of PQ were noted at term pregnancy and first days of life. Prenatal PQ did not affect postnatal weight gain nor did it impair somatic and neurologic development of the offspring. Pups born to PQ-treated dams showed reduced exploration and enhanced emotionality in the OF. PQ given in pregnancy, at doses greater than those recommended for malaria therapy, may affect pup postnatal survival and emotional behavior.


  • Malaria-induced Alterations of Drug Kinetics and Metabolism in Rodents and Humans

    by Ana C.A.X. De-Oliveira, Francisco J.R. Paumgartten

    Background:: Infections and inflammation lead to a downregulation of drug metabolism and kinetics in experimental animals. These changes in the expression and activities of drug-metabolizing enzymes may affect the effectiveness and safety of pharmacotherapy of infections and inflammatory conditions. Objective:: In this review, we addressed the available evidence on the effects of malaria on drug metabolism activity and kinetics in rodents and humans. Results:: An extensive literature review indicated that infection by Plasmodium spp consistently decreased the activity of hepatic Cytochrome P450s and phase-2 enzymes as well as the clearance of a variety of drugs in mice (lethal and non-lethal) and rat models of malaria. Malaria-induced CYP2A5 activity in the mouse liver was an exception. Except for paracetamol, pharmacokinetic trials in patients during acute malaria and in convalescence corroborated rodent findings. Trials showed that, in acute malaria, clearance of quinine, primaquine, caffeine, metoprolol, omeprazole, and antipyrine is slower and that AUCs are greater than in convalescent individuals. Conclusion:: Notwithstanding the differences between rodent models and human malaria, studies in P. falciparum and P. vivax patients confirmed rodent data showing that CYP-mediated clearance of antimalarials and other drugs is depressed during the symptomatic disease when rises in levels of acute-phase proteins and inflammatory cytokines occur. Evidence suggests that inflammatory cytokines and the interplay between malaria-activated NF-kB-signaling and cell pathways controlling phase 1/2 enzyme genes transcription mediate drug metabolism changes. The malaria-induced decrease in drug clearance may exacerbate drug-drug interactions, and the occurrence of adverse drug events, particularly when patients are treated with narrow-margin-of-safety medicines.


  • Open Access

    Ethical issues in placebo-controlled trials of COVID-19 vaccines

    by Ana Cecilia Amado Xavier de Oliveira, Francisco José Roma Paumgartten


  • Open Access

    Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues

    by Francisco José Roma Paumgartten, Ana Cecilia Amado Xavier de Oliveira

    When Covid-19 emerged in December last year, there was no vaccine nor was there specific effective treatment for this fast-spreading and life-threatening viral respiratory infection. Clinical trials were planned and are in progress to investigate whether drugs used for influenza, HIV and other viruses, and also anthelmintics (ivermectin, nitazoxanide, niclosamide), and antimalarials (chloroquine, hydroxychloroquine) showing antiviral activity in in vitro assays, are effective and safe for Covid-19. So far there is no convincing evidence that these antiviral and antiparasitic drugs are of any benefit for Covid-19. Notwithsanding the absence of evidence of clinical efficacy, these drugs are widely used outside of clinical trials (off label) for prophylaxis and treatment of this viral infection. The rationale behind the prescription of macrolide antibiotics (azithromycin) for Covid-19 is obscure as well. The widespread prescription and use of drugs of unproven efficacy and safety for Covid-19 is at odds with the rational use of medicines, a cornerstone principle of pharmacotherapy advanced by WHO in 1985. This irrational use of drugs is cause for concern because some of them are associated with serious heart disorders and deaths.